Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Other Non-Current Liabilities (2016 - 2025)

Ironwood Pharmaceuticals' Other Non-Current Liabilities history spans 14 years, with the latest figure at $21.6 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 26.56% year-over-year to $21.6 million; the TTM value through Dec 2025 reached $21.6 million, up 26.56%, while the annual FY2025 figure was $21.6 million, 26.56% up from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $21.6 million at Ironwood Pharmaceuticals, down from $22.2 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $39.8 million in Q3 2024 and bottomed at $1.5 million in Q2 2021.
  • The 5-year median for Other Non-Current Liabilities is $17.2 million (2024), against an average of $17.3 million.
  • The largest annual shift saw Other Non-Current Liabilities surged 478.86% in 2022 before it plummeted 44.14% in 2025.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $3.5 million in 2021, then skyrocketed by 178.95% to $9.8 million in 2022, then surged by 190.96% to $28.4 million in 2023, then crashed by 39.8% to $17.1 million in 2024, then rose by 26.56% to $21.6 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Other Non-Current Liabilities are $21.6 million (Q4 2025), $22.2 million (Q3 2025), and $22.5 million (Q2 2025).